<p>Public biotech Pyxis Oncology is taking forward its innovative work on ADCs. President and CEO, Lara Sullivan, explains the company’s journey to find the right investors, and why she believes the markets still have some learning to do when analyzing data from early-stage studies. </p>

Public biotech Pyxis Oncology is taking forward its innovative work on ADCs. President and CEO, Lara Sullivan, explains the company’s journey to find the right investors, and why she believes the markets still have some learning to do when analyzing data from early-stage studies.

Pharma Understands Phase One Data – But Does the Market?

Perspectives from the cutting edge of biotech and pharma.

The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series.

Lead today. Define tomorrow.

Business

News

Investing

Business News

Perspectives from the cutting edge of biotech and pharma. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series. Lead today. Define tomorrow.

Share Pharma Understands Phase One Data – But Does the Market?

Sign up to save your podcasts

Pharma Understands Phase One Data – But Does the Market?

Pharma Understands Phase One Data – But Does the Market?

More shows like Pathfinders in Biopharma

Pardon My Take

The Daily

Up First from NPR

The Readout Loud

Making Sense

Biotech 2050 Podcast

Business Of Biotech

BioCentury This Week

RBC's Markets in Motion

Biotech Hangout

Industries in Motion

Powering Sustainable Ideas

Macro Minutes

Strategic Alternatives

Goldman Sachs The Markets

The BioCentury Show